Ziel
Multi-drug resistant Gram-negative bacteria (MDR-GNB): the ultimate challenge!
Antibiotic resistance is a global public health concern recently elevated to the top three threats identified by the WHO, and subject of numerous national and international government activities. Although focused strategies have beneficially influenced infection rates due to methicillin resistant Staphylococcus aureus (MRSA), infections due to MDR-GNB are rapidly increasing. In a very recent report the Centers for Disease Control and Prevention concluded that Carbapenem-Resistant Enterobacteriaceae (CRE) represent an immediate public health threat that requires urgent and aggressive action (CDC: Antibiotic Resistance Threats in the United States 2013).
The epidemiology of MDR-GNB, and especially of CRE, is characterized by large heterogeneity in genotypes (with >20 reported resistance genes, such as NDM, KPC, VIM, OXA-48) and even larger heterogeneity of phenotypes, seriously hampering rapid detection of resistant types when using routine susceptibility testing. Treatment of infections caused by CRE relies on combinations of “older” antibiotics, lacking a strong evidence base of effectiveness and safety. New treatments for these infections are, therefore, urgently needed.
The COMBACTE-CARE consortium is building on the recently funded Topic 1a/b/c consortium: COMBACTE, and contains three networks: CLIN-Net, LAB-Net and STAT-Net. To fulfil the specific objectives of Topic 5 the consortium has focussed on capacity building in clinical sites in some of the new member states in south-eastern Europe, where infection rates with MDR-GNB are expected to be high. Together with high-quality study sites in countries with endemic levels of MDR-GNB (such as Israel and Greece) CLIN-Net and LAB-Net will maximize capacity to provide a highly efficient resource for the conduct of the proposed studies on ATM-AVI. Furthermore, the consortium brings in four of the most prominent MDR-GNB diagnostic research groups in Europe, able to address the diagnostic challenges for the epidemiological and clinical studies, and a highly successful – and already operational – cohort for biomarker identification in critically ill patients. Furthermore, the participation of the PENTA network offers the unique opportunity to efficiently include neonates and children in the observational studies.
The COMBACTE-CARE consortium brings together 20 academic partners (10 also partner in COMBACTE) and two CROs that build upon prior EU Commission investments which present unique expertise and capabilities to the overall project partnership.
For all these reasons, APC2 (aligned with the COMBACTE infrastructure) will (1) increase the efficiency of antibiotic R&D through analysing observational clinical and microbiological data sets and making recommendations for the development of novel antibiotic agents for MDR GNB; will (2) provide new knowledge on the clinical management and outcomes of patients (neonates/children and adults) with serious hospitalised infections and will validate this knowledge for clinical outcomes for patients in areas of emerging and endemic antibiotic resistance; will (3) support the sustainability of ND4BB supported investigator and laboratory networks (COMBACTE); will (4) conduct prospective clinical trials with novel trial designs to deliver safety, pharmacology, and proof of efficacy data for novel agents directed towards treatment of infections due to MDR pathogens, prevention or sequelae of infections due to priority pathogens; will (5) validate novel bacterial identification and follow-up diagnostics or clinical endpoints with the aim of reducing the size and cost of clinical trials; and will (6) provide new knowledge on biomarkers predicting poor outcome in patients with serious healthcare-associated infections.
Wissenschaftliches Gebiet
- natural sciencesbiological sciencesmicrobiologybacteriology
- medical and health scienceshealth sciencespublic healthepidemiologyepidemics prevention
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Programm/Programme
Aufforderung zur Vorschlagseinreichung
IMI-JU-09-2013
Andere Projekte für diesen Aufruf anzeigen
Finanzierungsplan
JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)Koordinator
CT13 9NJ Sandwich
Vereinigtes Königreich
Auf der Karte ansehen
Beteiligte (22)
3584 CX Utrecht
Auf der Karte ansehen
1211 Geneve
Auf der Karte ansehen
87000 Limoges
Auf der Karte ansehen
41071 Sevilla
Auf der Karte ansehen
50937 Koeln
Auf der Karte ansehen
64239 Tel Aviv
Auf der Karte ansehen
10561 Athina
Auf der Karte ansehen
75654 Paris
Auf der Karte ansehen
SW17 0RE London
Auf der Karte ansehen
10000 PRISTINA
Auf der Karte ansehen
Beteiligung beendet
9713 GZ Groningen
Auf der Karte ansehen
31096 Haifa
Auf der Karte ansehen
CF24 0DE Cardiff
Auf der Karte ansehen
28046 MADRID
Auf der Karte ansehen
08036 Barcelona
Auf der Karte ansehen
1105AZ Amsterdam
Auf der Karte ansehen
2000 Antwerpen
Auf der Karte ansehen
89081 Ulm
Auf der Karte ansehen
TW89GS Brentford
Auf der Karte ansehen
4058 BASEL
Auf der Karte ansehen
Beteiligung beendet
151 85 Sodertaelje
Auf der Karte ansehen
79106 Freiburg
Auf der Karte ansehen